@entity3144 associated with insulin aspart in a @entity1 with type 2 XXXX .

@entity1 @entity6 @entity1333 @entity4125 @entity272 @entity3144 @entity413
OBJECTIVE: To report a case of @entity3144 associated with insulin aspart therapy. CASE SUMMARY: A 56-year-old @entity1 was admitted to the Department of Endocrinology because of a poorly controlled Type 2 @entity6 . In an attempt to reach a tight blood @entity413 control, an intensive @entity6 management consisting of one evening dose of intermediate-acting NPH insulin and three preprandial doses of short-acting insulin aspart was introduced. Two weeks following insulin aspart introduction the @entity1 developed palpable @entity4125 on distal parts of the upper and lower limbs. Four days after the onset of @entity4125 , a skin biopsy was preformed. Histological examination showed @entity1333 with perivascular infiltrates of lymphocytes and erythrocyte extravasation. Direct immunofluorescence was negative. On the day the @entity4125 appeared, insulin aspart was substituted with regular @entity1 insulin. All @entity272 disappeared spontaneously within 8 days. Insulin aspart was not re-administered. DISCUSSION: Other possible causes of @entity1333 in this case were excluded by diagnostic tests. The temporal relationship between the insulin aspart administration and the occurrence of @entity4125 , with no further episodes of @entity272 after discontinuation of the drug, support the hypothesis of an insulin aspart caused @entity1333 . Based on the Naranjo's algorithm, the adverse drug reaction could be considered possible. CONCLUSION: Clinicians should be aware of the possibility of @entity3144 occurring during insulin aspart treatment.
